EUVIMEDEUVIMED entdecken
Crossref

Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy

L Parker Gregg, Aaron Perkins, Hui Yang, Christine Vu, Vijay Nambi, Wolfgang C Winkelmayer, S Susan Hedayati iD, Sankar D Navaneethan iD, Carlos A Alvarez iD

Journal of the American Society of Nephrology · 13.11.2026

DOI: 10.1681/asn.0000001313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 13.11.2026. Verfasst von L Parker Gregg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, TX.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are first-line treatment for hypertension in chronic kidney disease (CKD). However, guidelines do not recommend subsequent medication classes if additional blood pressure-lowering effect is desired.

Methods

This target trial emulation using national outpatient data from the Veterans Health Administration from January 1, 2010, to December 31, 2016, included adults with non-dialysis CKD stages G1-G5 on an ACEi/ARB who initiated treatment with a second antihypertensive medication, classified as a thiazide diuretic, loop diuretic, calcium channel blocker, or β-blocker. Outcomes included composite cardiovascular events (fatal or nonfatal myocardial infarction or stroke, hospitalization for heart failure, coronary revascularization), all-cause death, and composite kidney outcomes (dialysis initiation, kidney transplantation, sustained creatinine doubling). Clinically important characteristics were included as covariates in the analysis.

Results

Of 150,369 individuals already on ACEi/ARB treatment, 45,836 (30%) were prescribed a thiazide diuretic, 17,589 (12%) a loop diuretic, 33,172 (22%) a calcium channel blocker, and 53,772 (36%) a β-blocker. Those receiving thiazide diuretics and calcium channel blockers had the highest baseline blood pressure. Those receiving loop diuretics were more likely to have more advanced CKD or heart failure. Over a median (IQR) follow-up of 1282 (621, 1979) days, compared to thiazide diuretics, cardiovascular event risk was higher for calcium channel blockers, aHR 1.18 (95% CI 1.15-1.22), β-blockers, aHR 1.63 (95% CI 1.58-1.67), and loop diuretics, aHR 1.97 (95% CI 1.90-2.04). Composite kidney outcomes were also higher with calcium channel blockers, aHR 1.42 (95% CI 1.33-1.52), β-blockers, aHR 1.13 (95% CI 1.06-1.21), and loop diuretics, aHR 1.98 (95% CI 1.83-2.15).

Conclusions

Adding a thiazide diuretic rather than a calcium channel blocker, β-blocker, or loop diuretic on top of ACEi/ARB treatment was associated with favorable clinical outcomes among people with CKD.

Autor:innen und Institutionen

  • Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, TX.
  • Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness and Safety, Houston, TX.
  • Pharmacy Practice Department and Center of Excellence in Real-world Evidence, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX.
  • Department of Medicine, Cardiology Section, Baylor College of Medicine, Houston, TX.
  • Cardiology Section, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX.
  • Division of Nephrology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, NY.

ORCID-Profile: S Susan Hedayati, Sankar D Navaneethan, Carlos A Alvarez

Zitieren

APA

Gregg, L. P., Perkins, A., Yang, H., Vu, C., Nambi, V., Winkelmayer, W. C., Hedayati, S. S., Navaneethan, S. D., & Alvarez, C. A. (2026). Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001313

Vancouver

Gregg LP, Perkins A, Yang H, Vu C, Nambi V, Winkelmayer WC, et al. Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001313

BibTeX
@article{Gregg2026,
  author = {Gregg, L Parker and Perkins, Aaron and Yang, Hui and Vu, Christine and Nambi, Vijay and Winkelmayer, Wolfgang C and Hedayati, S Susan and Navaneethan, Sankar D and Alvarez, Carlos A},
  title = {Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001313}
}
Kostenlos starten →